SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

ANG Lifesciences - Quaterly Results

14 Aug 2022 Evaluate
The sales moved down -39.36% to Rs. 715.56 millions for the June 2022 quarter as compared to Rs. 1179.96 millions during the corresponding quarter last year.The company suffered a huge decline of -83.73% to Rs. 33.43  millions from Rs. 205.51 millions  of corresponding previous quarter.The company reported a degrowth in operating Profit to 114.04 millions from 292.01 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202206 202106 % Var 202206 202106 % Var 202203 202103 % Var
Sales 715.56 1179.96 -39.36 715.56 1179.96 -39.36 3486.69 1542.75 126.00
Other Income 1.23 0.79 55.70 1.23 0.79 55.70 9.52 7.46 27.61
PBIDT 114.04 292.01 -60.95 114.04 292.01 -60.95 660.33 156.74 321.29
Interest 31.75 13.37 137.47 31.75 13.37 137.47 78.50 35.77 119.46
PBDT 82.29 278.64 -70.47 82.29 278.64 -70.47 581.83 120.97 380.97
Depreciation 18.81 3.65 415.34 18.81 3.65 415.34 51.20 22.36 128.98
PBT 63.48 274.99 -76.92 63.48 274.99 -76.92 530.63 98.61 438.11
TAX 30.05 69.48 -56.75 30.05 69.48 -56.75 133.51 26.11 411.34
Deferred Tax 6.42 -0.58 -1206.90 6.42 -0.58 -1206.90 -1.14 -5.69 -79.96
PAT 33.43 205.51 -83.73 33.43 205.51 -83.73 397.12 72.50 447.75
Equity 103.67 51.83 100.02 103.67 51.83 100.02 103.67 51.83 100.02
PBIDTM(%) 15.94 24.75 -35.60 15.94 24.75 -35.60 18.94 10.16 86.41

ANG Lifesciences Share Price

33.65 -1.19 (-3.42%)
10-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1935.25
Dr. Reddys Labs. 1245.50
Cipla 1438.75
Zydus Lifesciences 1150.50
Lupin 2496.05
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: